WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Renée Maria Saliby: Kidney Cancer Research Champion

Renée Maria Saliby: Kidney Cancer Research Champion

Introducing Renée Maria Saliby, a dedicated young investigator in kidney cancer research! At just 27, Renée is blazing an inspring professional trail. Read on as she shares insights from her personal experiences and career pursuits, along with opportunities available for young researchers to...

SPRING ADVOCACY DAYS 2024 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

Empowering Young Voices: The Role of Youth in Kidney Cancer Advocacy

Empowering Young Voices: The Role of Youth in Kidney Cancer Advocacy

Scarlett Talcott, a vibrant 11-year-old from southern Montana, stands confidently in front of the Capitol Building during KidneyCAN's Advocacy Day. Living on a ranch with her parents, sister, and two brothers, Scarlett balances her love for the arts, crafting, and 4-H activities with a strong...

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

Renée Maria Saliby: Kidney Cancer Research Champion

Renée Maria Saliby: Kidney Cancer Research Champion

Introducing Renée Maria Saliby, a dedicated young investigator in kidney cancer research! At just 27, Renée is blazing an inspring professional trail. Read on as she shares insights from her personal experiences and career pursuits, along with opportunities available for young researchers to...

SUPPORT OUR WORK →

ROCK THE RUN 2023 →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

UT Southwestern – Cutting-edge Discoveries, Transforming Patient Care

The American Cancer Society estimates that in 2014, 63,920 people were diagnosed with kidney cancer and 13,860 people died from the disease. At UT Southwestern Harold C. Simmons Comprehensive Cancer Center, we are committed to the development of new therapies and the search for a cure.

In 2013, UT Southwestern formalized its commitment to the care of kidney cancer patients and research on kidney cancer by officially instituting a Kidney Cancer Program (KCP). The KCP includes more than 20 physicians, many of whom are renowned international leaders in their fields of urology, pediatric oncology, adult oncology, radiation oncology, radiology, and pathology. In addition, more than 40 scientists with their research laboratories are a part of the KCP.

The KCP builds on landmark discoveries made by scientists at UT Southwestern over the last three decades. Drs. Steven McKnight and David Russell discovered HIF-2α, a protein that mediates kidney cancer development. Subsequent studies by Drs. Richard Bruick and Kevin Gardnerled to the development of a drug that blocks HIF-2 activity. In addition, DJ Pan, Ph.D., discovered that the TSC1/TSC2 complex regulates TOR, which is the target of two kidney cancer drugs. Years later, James Brugarolas, M.D., Ph.D., discovered mutations in TSC1 in kidney cancer, and the presence of these mutations may identify patients most likely to respond to TOR inhibitors. Finally, recent discoveries by several investigators at UT Southwestern, including Payal Kapur, M.D., determined that there are different subtypes of kidney cancer with different biology and outcomes.

Source: https://www.utsouthwestern.edu/research/kidney-cancer/index.html